Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain

ABSTRACT

The development of newer classes of antidepressants and second-generation antiepileptic drugs has created unprecedented opportunities for the treatment of chronic pain. These drugs modulate pain transmission by interacting with specific neurotransmitters and ion channels. The actions of antidepressants and antiepileptic drugs differ in neuropathic and non-neuropathic pain; and agents within each medication class have varying degrees of efficacy. Tricyclic antidepressants (e.g.; amitriptyline; nortriptyline; desipramine) and certain novel antidepressants (i.e.; bupropion; venlafaxine; duloxetine) are effective in the treatment of neuropathic pain. The analgesic effect of these drugs is independent of their antidepressant effect and appears strongest in agents with mixed-receptor or predominantly noradrenergic activity; rather than serotoninergic activity. First-generation antiepileptic drugs (i.e.; carbamazepine; phenytoin) and second-generation antiepileptic drugs (e.g.; gabapentin; pregabalin) are effective in the treatment of neuropathic pain. The efficacy of antidepressants and antiepileptic drugs in the treatment of neuropathic pain is comparable; tolerability also is comparable; but safety and side effect profiles differ. Tricyclic antidepressants are the most cost-effective agents; but second-generation antiepileptic drugs are associated with fewer safety concerns in elderly patients. Tricyclic antidepressants have documented (although limited) efficacy in the treatment of fibromyalgia and chronic low back pain. Recent evidence suggests that duloxetine and pregabalin have modest efficacy in patients with fibromyalgia